243 related articles for article (PubMed ID: 32766688)
1. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials.
Cupido AJ; Kastelein JJP
Cardiovasc Res; 2020 Sep; 116(11):e136-e139. PubMed ID: 32766688
[No Abstract] [Full Text] [Related]
2. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
3. Inclisiran in lipid management: A Literature overview and future perspectives.
Scicchitano P; Milo M; Mallamaci R; De Palo M; Caldarola P; Massari F; Gabrielli D; Colivicchi F; Ciccone MM
Biomed Pharmacother; 2021 Nov; 143():112227. PubMed ID: 34563953
[TBL] [Abstract][Full Text] [Related]
4. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
5. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
6. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
7. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M
Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005
[TBL] [Abstract][Full Text] [Related]
8. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
[TBL] [Abstract][Full Text] [Related]
9. Nonstatin Therapy for Dyslipidemia.
Ahmed HM; Nissen SE
Circ Res; 2018 Oct; 123(9):1036-1038. PubMed ID: 30355163
[No Abstract] [Full Text] [Related]
10. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou S; Ray KK
Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
[No Abstract] [Full Text] [Related]
13. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
[TBL] [Abstract][Full Text] [Related]
14. A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran.
Asbeutah AAA; Asbeutah SA; Abu-Assi MA
Am J Cardiol; 2020 Aug; 128():218-219. PubMed ID: 32482309
[No Abstract] [Full Text] [Related]
15. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
German CA; Shapiro MD
BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
[TBL] [Abstract][Full Text] [Related]
16. LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase.
Wu L; Soundarapandian MM; Castoreno AB; Millar JS; Rader DJ
Circ Res; 2020 Sep; 127(8):1112-1114. PubMed ID: 32808882
[No Abstract] [Full Text] [Related]
17. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
Hohenstein B; Tselmin S; Bornstein SR; Julius U
Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
[TBL] [Abstract][Full Text] [Related]
18. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
19. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
20. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
Wright RS; Collins MG; Stoekenbroek RM; Robson R; Wijngaard PLJ; Landmesser U; Leiter LA; Kastelein JJP; Ray KK; Kallend D
Mayo Clin Proc; 2020 Jan; 95(1):77-89. PubMed ID: 31630870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
